Improving the Response of the Ovarian Tumour Microenvironment to PARP Inhibitors

改善卵巢肿瘤微环境对 PARP 抑制剂的反应

• 批准号: 466593
• 负责人: Farokhi Boroujeni Salar
• 金额: $ 1.27万
• 依托单位: University of Ottawa
• 依托单位国家: 加拿大
• 项目类别: Studentship Programs
• 财政年份: 2021
• 资助国家: 加拿大
• 起止时间: 2021-12-01 至 2022-12-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=466593&lang=en
• 关键词: Anti-Pd-L1; Brca 1 Mutations; Brca 2 Mutations; Extra-Cellular Matrix; Homologous Recombination Deficiency; Niraparib; Olaparib; Ovarian Cancer; Parp Inhibitors; Tumour Microenvironment

Ovarian cancer is the most lethal gynecological cancer and has a 5-year survival rate of less than 45%. About 20% of patients with high-grade serous ovarian cancer have mutations in the genes. These genes code for the proteins in one of the main DNA repai

卵巢癌是最致命的妇科癌症，5年生存率低于45%。大约20%的高级别浆液性卵巢癌患者有基因突变。这些基因编码的蛋白质在一个主要的DNA修复，